The presentation of primary registrational data in SPS significantly de-risks the KYSA-8 program and supports a potential Biologics License Application (BLA) submission. Traders should monitor the AAN presentations in April 2026 for detailed efficacy and safety data, which could catalyze upward re-rating. The initiation of a randomized Phase 3 in gMG also strengthens the durability of miv-cel’s clinical narrative.
Price Chart
Executive Summary
Kyverna Therapeutics announced selected presentations at the 2026 American Academy of Neurology (AAN) Annual Meeting, including a late-breaking oral presentation of primary analysis from its registrational KYSA-8 trial of miv-cel in stiff person syndrome (SPS), and updated Phase 2 data in generalized myasthenia gravis (gMG). The company highlighted statistically significant clinical benefit across all endpoints in SPS, including reversal of progressive disability, and plans to present Phase 3 design for gMG, signaling advancement toward potential regulatory filings.
Key Facts
- Primary analysis from the KYSA-8 registrational trial in stiff person syndrome (SPS) will be presented orally at AAN 2026, confirming statistically significant clinical benefit across all primary and secondary endpoints.
- Miv-cel demonstrated ability to reverse progressive disability in SPS, a rare and debilitating autoimmune disease with no FDA-approved treatments.
- Updated Phase 2 data from the KYSA-6 trial in generalized myasthenia gravis (gMG) will be presented, along with the design of the upcoming global Phase 3 randomized controlled study versus standard of care.
- Miv-cel (KYV-101) is a fully human, autologous CD19 CAR T-cell therapy designed to deliver durable, drug-free, disease-free remission with a single dose.
- No new safety signals were reported, and the therapy continues to show a favorable tolerability profile.
Financial Impact
High potential long-term value given the registrational data in SPS and advancement toward Phase 3 in gMG, two large unmet need indications. Market opportunity could exceed $1B+ in peak sales if approved.
Risk Factors
- Clinical data to be presented may not meet investor expectations despite 'positive topline' characterization.
- Regulatory path remains uncertain; FDA may require additional trials before approval, especially in a novel modality like CAR T for autoimmune diseases.
- High valuation sensitivity to clinical execution; any safety signal or efficacy shortfall could trigger sharp downside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250697 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.27 (−9.61%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.27 (−24.61%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.27 (−33.46%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.27 (−46.28%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.27 (+34.57%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.27 (−41.44%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.27 (−48.48%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.27 (−53.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers